Get the Latest Investment Ideas Delivered Straight to Your Inbox.


Biopharma 'Keeps Executing and Securing Milestones'
Research Report


The company's latest achievement and partnership potential are addressed in a ROTH Capital Partners report.

In a Dec. 12 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Daré Bioscience Inc. (DARE:NASDAQ) received U.S. Food and Drug Administration (FDA) approval to clinically advance its Sildenafil cream into a Phase 2b at-home study, "getting one step closer to the first potential approved treatment for female sexual arousal disorder."

Rahimi highlighted that Daré may move forward with the 12-week, placebo-controlled study without having to submit further data, and is preparing to do so. The company will develop screening guidelines and a primary study endpoint from the patient-reported outcomes it collected previously. As for exploratory endpoints, Daré and the FDA agreed on those, which "could potentially be included as endpoints in a future Phase 3 trial," the analyst added.

She also pointed out that "Daré's continued strong execution and on-track program updates will attract significant interest from potential strategic partners and strengthen our confidence in Daré's commitment to delivering on key inflection points for topical Sildenafil, BV1, Ovaprene and its other women's health assets." The company could strike up licensing deals at the upcoming J.P. Morgan Healthcare Conference.

A single, pivotal Phase 3 trial is expected to start this quarter for BV1, a vaginal infection treatment and the "crown jewel of Daré's pipeline," Rahimi noted.

ROTH's target price on Daré is $6 per share, and the biopharma is Buy rated. The stock's currently at $0.82 per share.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from ROTH Capital Partners, Daré Bioscience Inc., Flash Note, December 12, 2019

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Within the last twelve months, ROTH has received compensation for investment banking services from Daré Bioscience, Inc.

ROTH makes a market in shares of Daré Bioscience, Inc. and as such, buys and sells from customers on a principal basis.

Shares of Daré Bioscience, Inc. may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.

Within the last twelve months, ROTH has managed or co-managed a public offering for Daré Bioscience, Inc.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.

Learn More about Which Online Broker is Right for You?

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe